FOLH1 and prostate carcinoma: Three radiopharmaceuticals (68Ga-PSMA-11, 18F-DCFPyL [18F-piflufolastat], and 18F-flotufolastat [18F-rhPSMA-7.3]) that target the PSMA receptor are US Food and Drug Administration (FDA)-approved for imaging patients with recurrent prostate cancer [5,6,7].